-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

Benzinga·08/06/2026 17:06:30
Listen to the news
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.